<SEC-DOCUMENT>0001144204-16-120448.txt : 20160822
<SEC-HEADER>0001144204-16-120448.hdr.sgml : 20160822
<ACCEPTANCE-DATETIME>20160822080014
ACCESSION NUMBER:		0001144204-16-120448
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160822
FILED AS OF DATE:		20160822
DATE AS OF CHANGE:		20160822

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dehaier Medical Systems Ltd
		CENTRAL INDEX KEY:			0001474627
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34661
		FILM NUMBER:		161844228

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 501, JIUZHOU PLAZA
		STREET 2:		83 FUXING ROAD,
		CITY:			HAIDIAN DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100856
		BUSINESS PHONE:		(8610) 5166-0080

	MAIL ADDRESS:	
		STREET 1:		SUITE 501, JIUZHOU PLAZA
		STREET 2:		83 FUXING ROAD,
		CITY:			HAIDIAN DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100856
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v447449_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>U.S. SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of August 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-34661</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dehaier Medical Systems Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dehaier Medical Systems Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Room 501, 83 Fuxing Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Haidian District, Beijing 100856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">People&rsquo;s Republic of China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
&nbsp; &nbsp; &nbsp; Form 40-F&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cautionary Note Regarding Forward-Looking Statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Report, including the exhibits included herein, may contain
forward-looking statements.&nbsp;&nbsp;We have based these forward-looking statements on our current expectations and projections
about future events.&nbsp;&nbsp;Our actual results may differ materially from those discussed herein, or implied by, these forward-looking
statements.&nbsp;&nbsp;Forward-looking statements are generally identified by words such as &ldquo;believe,&rdquo; &ldquo;expect,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;project&rdquo; and other similar
expressions. In addition, any statements that refer to expectations or other characterizations of future events or circumstances
are forward-looking statements. Forward-looking statements included in this Report are subject to significant risks and uncertainties,&nbsp;including
but limited to:&nbsp;risks and uncertainties&nbsp;associated with the integration of the assets and operations we have acquired
and may acquire in the future; our possible inability to raise or generate additional funds that will be necessary to continue
and expand our operations; our potential lack of revenue growth and other factors&nbsp;detailed in the Company&rsquo;s filings
with the Securities and Exchange Commission. These forward-looking statements involve certain risks and uncertainties that are
subject to change based on various factors (many of which are beyond the Company&rsquo;s control). The Company undertakes no obligation
to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as
required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 22, 2016, Dehaier Medical Systems Limited (the &ldquo;Registrant&rdquo;)
issued a press release announcing the closing of a previously announced securities purchase agreement (the &ldquo;Securities Purchase
Agreement&rdquo;) with Hangzhou Liaison Interactive Information Technology Co. Ltd. (&ldquo;Liaison Interactive&rdquo; or the &ldquo;Purchaser&rdquo;),
a publicly listed company on the Shenzhen Stock Exchange (Trading Ticker: 002280). On August 18, 2016, Liaison Interactive completed
the purchase of US$20 million of the Registrant&rsquo;s common shares and warrants to purchase common shares. A copy of the press
release is attached as Exhibit&nbsp;99.1 hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Share Purchase Agreement (the &ldquo;Agreement&rdquo;),
the Company sold 11,111,111 restricted common shares for a purchase price of US$1.80 per share for an aggregate of US$20,000,000
to Liaison Interactive. Liaison Interactive and its designees will also receive warrants to purchase 1,000,000 restricted common
shares of the Company at a purchase price of US$2.20 per share. Dehaier Medical previously announced the sale of 620,414 shares
on June 6, 2016. The final closing involved the sale of 10,490,697 shares. The warrants may be exercised at any time after issuance.
If fully exercised, the Registrant would receive aggregate gross proceeds from the warrants of $2.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The investment funds after deducting fees and expenses (including
expenses associated with the repurchase of certain outstanding warrants held by third parties) will be used for the development
and marketing of Dehaier Medical wearable sleep apnea products business, and potential mergers and acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 86%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated August 22, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities and Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEHAIER MEDICAL SYSTEMS LIMITED</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 22, 2016</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ping Chen</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ping Chen</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief Executive Officer</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Principal Executive Officer) and</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Duly Authorized Officer</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 48pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated August 22, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v447449_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"><IMG SRC="tlogo.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 28.1pt"><FONT STYLE="font-size: 12pt"><B>Dehaier
Medical Systems Ltd. Completes $20 Million Strategic Financing with Hangzhou Liaison Interactive Information Technology Co. Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.4in">Beijing, China &ndash;
August 22, 2016, Dehaier Medical Systems Ltd. (Nasdaq: DHRM) (&ldquo;Dehaier Medical&rdquo; or the &ldquo;Company&rdquo;), which develops,
markets and sells medical devices and wearable sleep respiratory products in China and international markets, today announced that
the Company has completed its final closing under $20 million strategic financing with Hangzhou Liaison Interactive Information
Technology Co. Ltd. (&ldquo;Liaison Interactive&rdquo; or the &ldquo;Purchaser&rdquo;), a publicly listed company on the Shenzhen
Stock Exchange (Trading Ticker: 002280).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.4in">Pursuant to the Share
Purchase Agreement (the &ldquo;Agreement&rdquo;), the Company sold 11,111,111 restricted common shares for a purchase price of US$1.80
per share for an aggregate of US$20,000,000 to Liaison Interactive. Liaison Interactive and its designees will also receive warrants
to purchase 1,000,000 restricted common shares of the Company at a purchase price of US$2.20 per share. Dehaier Medical previously
announced the sale of 620,414 shares on June 6, 2016. The final closing involved the sale of 10,490,697 shares. The investment
funds after deducting fees and expenses (including expenses associated with the repurchase of certain outstanding warrants held
by third parties) will be used for the development and marketing of Dehaier Medical wearable sleep apnea products business, and
potential mergers and acquisitions. The Liaison Interactive investment will dramatically improve the Company&rsquo;s ability to
expand wearable medical device business and to launch other new smart wearable devices and mobile medical solutions over the next
few years. It is an important step in the strategic transformation of the Company. After this investment, the company expects a
more interactive and solid relationship with Liaison Interactive that will leverage Liaison&rsquo;s resources, promote the development
of Dehaier Medical&rsquo;s intelligent medical business, accelerate the Company&rsquo;s industrial layout on intelligence medical
market, and further optimize Dehaier&rsquo;s overall business strategies to increase market penetration and acceptance. Through
this investment, Liaison Interactive will benefit from Dehaier Medical&rsquo;s access to the medical intelligent hardware market,
expanding its intelligent hardware expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.05pt 0pt 0; text-align: justify"><B>About Dehaier Medical Systems
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.05pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.4in">Dehaier Medical
develops, markets and sells medical products, including medical devices and wearable sleep respiratory products in China and international
markets. The company develops and assembles its self-branded medical devices and sleep respiratory products from third-party components.
Dehaier is committed to becoming the solution provider of medical smart wearable devices and professional services. Dehaier is
transforming from a traditional medical equipment supplier to a high-tech enterprise in the field of mobile medical and smart
wearable devices. The main business of Dehaier is providing overall solutions including accurate screening, efficient treatment
and treatment evaluation for obstructive sleep apnea syndrome (&ldquo;OSAS&rdquo;) patients. With the cutting-edge photoplethysomography
analysis technology and state-of-the-art sleep diagnosis device, Dehaier made the first application of cloud technology in sleep
medicine by managing to upload patients&rsquo; records, patient information management, and analysis to the cloud. Dehaier Medical
provides sleep diagnostic products and services for inpatients and outpatients in Chinese medical institutions including chronic
diseases therapy departments in public hospitals, patients in private physical examination centers and VIP customers of life insurance
companies. Dehaier Medical&rsquo;s technology is based on six patents and eleven software copyrights. More information may be
found at <U>http://www.dehaier.com.cn</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Hangzhou Liaison Interactive Information
Technology Co. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.4in">Liaison Interactive,
formerly known as Beijing Digital Grid Technology Co., Ltd. was founded in 2007 as a leading mobile Internet product and services
provider in the industry. On October 24, 2014, China Securities Regulatory Commission approved the asset restructuring application
of Beijing Digital Grid Technology Co., ltd. and the listed company Hangzhou New Century Information Technology Co., Ltd. After
the restructuring, listed entity Liaison Interactive (002280) became China&rsquo;s first listed mobile Internet company. Liaison
Interactive has three core business units. Digital Grid Department focuses on innovations in products and technologies. Interactive
Entertainment Department focuses on mobile game developing and operating. Intelligent Hardware Department focuses on one of most
important business strategies striving to be a world-class developer. Based in Beijing, Liaison Interactive has set up subsidiaries
and branches in Shanghai, Guangzhou, Hong Kong, Shenzhen, Hangzhou, Nanjing, Shenyang and the U.S. For more information, please
visit <U>http://www.lianluo.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For more information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dehaier Medical Systems Limited</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mary Li</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+86 10-5166-0080 ext. 211</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">investors@dehaier.com.cn</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ /0#) P$1  (1 0,1 ?_$ *T   $#!0$! 0
M      D !P@! @,&"@4$"P$  04! 0$               $" P0'!08($
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M ,QR&4(42F QRE_5V )0$QB_$ Z["'3J&DS1YI*\E=\PD(@4#=QNT#;% QA
MIA[0$VQ1[>OV[:<"#@BO)(5T@*!Q.7M-MVF =P,(CL!2[ /<<1'8"AU$?AH0
MYY*@.$3?I5(/YC%V P;B8@B4P 'J(E$H[_9MI:)/4KA5( "(G#8 $PC\.T/C
MOZ;:*(]21E2$(!SF I!#<##N ;#Z;].F^_QTA(&*49E452!^H0+N(%#NW* B
M(B4  3  "(B4=)FCS17DE[A=P#?J(B !U$>G0>@!OTT9H\T5Y)"J0![1,4#?
M8(@ ]1  V ?4!$=O].DS1YHKR2]U/\OYR_F#<OY@#N^ ]N_KL/K]FC-'FBO)
M6@NF8=@, ]-QVWV#X[".VP&V^'KI<T>:*\E0'"!Q,0%"F,4-S$+N8Y #;?O*
M =Q!Z_';0)!Z8H()#%5]U( ,/>':0=C#L.V_:)AV';8VQ0W';?;3G2"+8+![
MZ'_>2_\ (3^_2)R:')USL-6 GTAY7FR9T#CWRM>LTZH0X%'82IP#I+N$!^ @
M&NAI[&>(F06?FSKFZS4"U"1!J @_\G,ZYT%,Q'.7\EUV&54.<O\ EXTQY@:(
M% #"'9_F+?EK%>3I[=!^6:=Q?4O4 UJO:VR[3J@;5VQ :B3$"YFE$@8D -E/
MOJLZWK>]5"#VR6\D&+*$ZWF)!R]GIB2NR:K==)<;MG3E-G1=4ZPF!9-=I#/:
M'3!*Y*(E.1 GM' =@'8=;EL?;6FSB=O3&-D2J\8_%ZEN(JLSUN_ZQY0!.8A,
MOBG._P I.*8+L2#.4*E#61KA^'4K;RI0EEQQ(;2-ZXJ'1L5DL4R^9J(I&EZ<
M\64*O"S2!02,7NUT=Y[0L7+LM7HLO2C61RNTA],L,1@>8\ZKD:/<[UVYT+Q/
M4Y.MI<9!DX>6;+PUA(\=.I*#N6/K/8 (#:9GG\8[KU+L%G2'^5\EG*K)/,<Y
M(:'V2//-&CA<HF, ZMZ7MN&MT'68F CED0\6YD8D-C$X@<5+J=1;M7&S#,*^
M/FB9>.SGF\K=*N'&J'5EX_'T&R0R1B#(#],THMB?#5DG%X.:P_816.*HY0I^
M1$W-:K4:H7W'P"BKMV)ZP_\ (O8EK2:H:^R/XI!I "AEP/E1\Q.  KST#M+N
M:5VST\Q88>0P/Z(PN.\R2$0[:0Q2'?&3>&C7D(L[*\4CGC=/YM[7$Y)0X&>R
MD(W.#FSRSDYV[%P/RZ90,&VLNU^V:>.D,H$=,?$_^1Y GZ10G$T6CZ/<,\\S
MU\>"IO5NXPMI:MG,:[24*Z;&=HD.(%4<-BG,B+UL4W:L:/.J4027,4I%0V$H
MCOKRUVS*T'EX]J]/9U%JXV4O)<J?F[\J/-OC/SEXR<2N,K@V-*QDE2KH3MW=
MTJ&OLY>7USM#>$,VJT*H=9^*=936 J93%3!TX.8@"(%';GW)&9:&*ZUH0$'+
M.F)YB>=3E-A-+D)3L-9VX]99M^$UY"O2%<C^/F2S9"K#6.<A!2-DN,^K8%:=
M"OV#WJY75;E9"MT3+MTU6ZDX^GDK,=()M,<5&;B-YX_(<RIMRG>1N;L/1DTW
M)'3J=<ROQXOBLE4*'[9"LL@?/T):"BVU8LBBX)-G#LHIJ&#<#==)UIA+]F#P
M1^;KY \\2_AUM'.:B9!QNXRA'L'5@K]RQ?BJQ7&@2C*%M)8DC25HUD>OYN-:
M/4$3MWKT55"L#G*Y*'ME$ GC)XYBJ<[=D7<A-4.O%?FRYNVWQ0SG).\U7"5(
MSO:,CM\<8AS%;9Z&KN&K'&R1G#A]+/J^R"4.TM59!@LR".7;D!<-EP,)?4SQ
M9Z)XTHD:.WCBM'P?YH^5E>Q@K/9I\@OB]M5Q%LXEG<!(4[*)9JK P;J=L&R=
M48(&O3L@[ I0(/:GU'8QA$= O !@4[[7R18O$UY)[WY!;3D!5[ESBY>JU2JG
M'/)6J8?JN2JKD.OSLO)E)$N9P;E/2\:,(HBV=!NAN<J@%] '3Q>>CA1W;0MQ
MK1"CYI^6'R;\@/)"WX:>,.O+PE"@'@T:5O5QQLZ"O6&UQIGG]:6R5M\]&*,8
M&H1!P%JF9$0[_:!0@&.?45VY+-1%JW9E$R<%E/B"\DG/*.RM'\678>,>=Y%Q
MCIO2WV/5^1E^:7*2M4<Q2.HV<QJ,$1JVDW1B&5.U(&^X[;!Z:;U)@Y6!\>U2
MG20R=4$B+/A\E&[&_G8Y^9%YOPW"&-X,8YE+*ME-+'MCR5!R62I#&+!M$/$D
M[;:&=H=)-FCR)@D 6,0YM@,9+IW (:DMRE,,U5%/3VX#,9'*I)^>KRW9_P#%
M@QXWO,+TW'EO-EYUD,MC)>VDJ[59C4TZ\HQ+&_3'[$Y"JJ3JH&$XC^1,NVP[
M[J2 /)-MV[=RD2]5"6Z>;KFOCF>Q33;/D#BG*9%R7C>M9+=TS'?'_-N0EZ#"
M6:,++I)7&8B[>DF@[8Q)OFW/M%.": "([>FDSQ'$,G=&V21Q"W^G>9SD-DES
M(,,:\R>!&1G44R:.Y1"B\=N2]G<0Z3T0!!9XWAY)VHS336_E;J]H KTTH+BF
M">=-$!S@CN,>0>5<)<([/R8Y0,JA=;10\?2F49IGA6*G:U%3U5%$DK!M(^.N
MCE]*1,X:..0KLBYB@F<FQBAL.GY2SE0=.$I].)KAQ0(.7'[CO(V/HGA#:>-_
M&VE6>"YJ4].8@8[+U@FV\U7YZ3NZU$CHQZ_K#UBP;LE')"&65%,XD(;N#<.F
MF&< 5-]F0*NM^R?S;\RJ=_KZ4;E'P[X5;TY=NWOF*)OD]'RLK/N$W":[J-FW
MUG2//5%PBALV[4!2./?W^H .GQ-<U&3>C'Z0YDIG<=^7GDWR_EFHUJ6HGC(L
M]!-+L#Y'=80Y43U\R+ 4I55 TI,0%<(9=-XZ9HK =(5=DC'$I>F^X2B0/M4-
MR&0Y9.CA]@_]YQ_P)?\ +IU%!1-'F%B8];.X 9$>U7L.1@U=/C]AP$##[+%[
M'+;?<)^OIKK[;?A"X(W&,'"X^ML9@7P0/^6475(F,>SUADHN!03,D@C+6:?Q
MEAY$5Q Z_M+S%\D+O<W9R)$$XA&1AC"4!$.NMH[5ZE^]"U8S$7,)",IY9>;#
M*(^TK+.Y+NGT\"Y (]R!1DSDOQQ822D>-SJ5K=I%*HW)4JKGK,"[DBJ*JQ%6
MEAG%\:TV0141;G/WMT?9$A#"GN :^D.W]IW:1MVKL9Q@) &3AI#C( $MS8X+
M(M;K=/<E(P/J91VJM2RMS@?SD;Q"QODRZ6S&QX6S*R\5C"AX_;UR0*[!:$<(
MRW];S\X0'!TB[!_U52[@8-M]>AW;N?M[L2_<TV_&$;5YQ%R ]//^JXEO;]TW
MR)AM E+6QQ;]$UV7,AY&E)]3"SRDS,1GM:P.8.7QNJR4"2K^0;)(-&62Z>5N
MU#M3KL[,(,+5%*; 5G*E65*($$==;MN>USVR>Z1(_P!1=CFCR8BA=5KMO<-(
M?]?KG^_!8\T4'C^5#"E)8I(V6.=6>1G)S(%FOZZ2;F$R'F&";*1MRS>NB3N(
MMAWC9'O5(^J]NY++D!V8Z0'*0A]8AW7ISNFY2F1<CH&;D!$EV:H>;#,#A!@6
M*T'80-':<M^OC^J)'AW*TBT63A7L5+/#@K5:D-$5466L,A.V8_U/%. ?J!3>
M\^MMF(J>X90<E'W&X*%:G, !L.)]P;;"%\FW(?9U.;+PC]4L&;]MNI!X%Z+0
M=IUL[MP1B"WBG^5T'8PQV\I$&5Q.+EL%VEDF[VW3A$_9;NWYDR%-#0[?M*5C
M6H9+^2P;)@5,I$P.?\PCK'==J(R,A:_]0)RCRYGS/%:SHM+TX1,FS-7QR7#K
M^Z#ATL8^2'A9E>@N9>L9,GJ[#.GMPC7[H) CNN7=NC"N(D5U5$8E:*2<',FH
M@D'8?8WYCB(ZX<9F,W\<%Z*Q 7(,HZY"P7?\5YQ\CT)15\U6,_*NM7&N9W:1
MN'*3?GJ./D)%ID&;L5*%"\)2J*T2X$5%79T#[(;F%,?@$YB3S5\>D"/):9"9
M?R;R?QYF.YTFP9/L^/,K<=:;P7O=MBN.5)C&:-'QF+>7BH>#=/;Z@5I?OEV9
M3.GW8H!R;[D)MI&3LQ)!Y+HKNE&?<5OVU5XJ=!?9*K$A!8$<*>]D"(9UV],P
MMMW0"3:OHQHJ\8@SD(Z242+V*'*NR5 2CN<-6(![3?M7*E 2U1)XU7'_ "3.
M[MO [!_2ZO5U,:R7.$'%KN3JPO271M>&58=,(2!A:L9LNP)7'46D8[IX50AD
MC;%$N_74,HMBNM",8!AR3KX K62IR0XBT^7X[0\FC(<:[%9<5J2-FCZKAC)]
M>C(R<D592[2Q:J_<'M9WB!A,@JN<YUDDR=Q>[;30 I'CY(EW[0-]? SMRU3A
MZS#OJ/(4JEDO$\YD093=6D2.YQ:N-H2%$ACSC66<)*IK"!B"B %-_O;:FMP<
MU5#6P!@[^*IT/W"'D$R1E/EABGQE\&9QW7[>SN4$GE:T8O7"'F[)E&SN&[&%
MHRLS6T4) 8NE-I0[J1*)R_XA0X*A_AM]-O$B3%5]#&,2YYH'S;@U9EO,RMPD
M'-E]+E%&[K5-+-PS;A6W*94;U87Z<RK-'53?F;?7-T/F?=%8R8[F_+J-I9LG
M'!=4S@;/6_:SHU7[>/R%9.P3S!R=XW.9TXZ=6.RW6QQ6/['=S$4GJSEN 44B
MYFEDG'B2;]6*O3-D!FIC*&*JN"()"/NCO/ISZ9!<Z_;$H2D.'C_A;M^\H#NB
M.#I#"3O^8S<JJ90H^S["2%#.8%$DMW(@13M+T#8 ZCZ:=/Z4NVVP22IJ9PRE
MG+AUXY<<<JX2]<.:#B8_%W'M>@XR\8@E;!GBSVVPT=&#D:[%6N&53&37E7+H
MXH'W]M! /YVQ-15$.#>RJ.E ZJ43FS CV<_ 0#O )D;-N \R6.MU;+6*N-^3
M^84*T7Q<ER8Q=<GE&R7!-)5ZZ27I=NC%&$61VK*H&03;G5,1RH(%(83;!J2T
M6"LZBW"5JKEJAEWG9(QG:LG<)<JXJY;WFJ)2UJP[D.$RQD3%D>^BJQ%0SV,D
ME74_#1DRH=T 1D+V*K)F$Q3F1-L8 .&K$7,2^*Y4&A=!B*<'7YR?+12AIS?B
MQK&&,Y2N?<'XPN$!C;&MVL&)G^')]1E"9V9*/HR0:K/'PV S5X8R8/P332.
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M*OBV;@30\O8:C3&B]<?9"M#%^V0E(D97(R+M1H!P+NR12Z;#OJ#J' DLINB
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M6K8]I81T5D-NJTO"TM8K/992R,3,#Q1(^0GK))2,N2.:1K@Z2"22I$T0-N4
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@6A"6A"73K_'_ &_V:$):$):$):$):$):$):$):$+_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
